GI Innovation Company Description

GI Innovation, Inc., a bio-venture company, engages in the research and development of protein new drugs.

The company is developing GI-101, an immune anticancer drug with novel dual fusion protein in Phase I/II clinical trial; and GI-301, an IgE-mediated allergy treatment designed as a fusion protein that is in Phase I clinical trial.

It is also developing GI-10N, an immuno-oncology drug; GI-30N, a drug for allergic and fibrotic diseases; and GI-20N, a drug for metabolic diseases.

The company was founded in 2017 and is based in Seoul, South Korea.

GI Innovation, Inc.

Country	South Korea
Founded	2017
Industry	Biological Products, Except Diagnostic Substances

Contact Details

Address: Munjeong Station Terra Tower Seoul, 05855 South Korea
Phone	82 2 404 2003
Website	gi-innovation.com

Stock Details

Ticker Symbol	358570
Exchange	KOSDAQ
Reporting Currency	KRW
SIC Code	2836